Investor Presentaiton
Immunology
LPA₁
Sotyktu
CD19 NEX T
Potential transformative treatment option for patients with
certain severe immunologic diseases
BMS-986353 expresses the same CD19 specific CAR
construct as best-in-class Breyanzi 1,2
Anti-CD19 Targeting Domain 1,2
Extracellular single-chain variable fragment to
recognize CD19
CD28 Hinge/Transmembrane Domain³
4-1BB Costimulatory Domain 1,2
Stimulates CD8+ central memory T-cell
generation and favors CAR T-cell persistence4
CD3-Activation Domain 1,2
Breyanzi achieves rapid and complete B-cell depletion
in patients with B-cell malignancies
NEXT: Next generation technology manufacturing
platform balances speed and robustness
Faster turnaround time
Optimized cell expansion time
Increased productivity
•
Leverages a closed and automated
manufacturing platform leads to increased
yield and lowered cost
Innovative technologies
Proprietary harvest technology improves purity
CD19 NEX T: Differentiated safety profile of Breyanzi with an enhanced manufacturing process
1. Makita S, et al. Drugs Context. 2019;8:212567. 2. Teoh J, et al. Blood. 2019;134:593. 3. Jayaraman J, et al. EBioMedicine. 2020;58:102931. 4. Weinkove R, et al. Clin
Ill Bristol Myers Squibb Transl Immunol. 2019:8;e1049.
Not for Product Promotional Use
69View entire presentation